Evercore ISI Cuts Health Catalyst (NASDAQ:HCAT) Price Target to $3.00

Health Catalyst (NASDAQ:HCAT) had its price objective cut by Evercore ISI from $4.00 to $3.00 in a research report released on Wednesday morning, Marketbeat reports. The brokerage currently has an in-line rating on the stock.

HCAT has been the subject of several other reports. Summit Redstone set a $5.00 target price on Health Catalyst in a report on Friday, August 29th. Canaccord Genuity Group lowered their price objective on Health Catalyst from $9.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, August 29th. KeyCorp lowered their price objective on Health Catalyst from $5.00 to $4.00 and set an “overweight” rating for the company in a research note on Wednesday. Wells Fargo & Company lowered their price target on shares of Health Catalyst from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, August 11th. Finally, Citigroup lowered shares of Health Catalyst from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $6.50 to $3.50 in a research report on Friday, August 8th. Three research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $4.55.

Health Catalyst Price Performance

Shares of NASDAQ:HCAT opened at $2.65 on Wednesday. The company has a market cap of $186.48 million, a PE ratio of -1.75 and a beta of 1.62. The firm has a 50-day simple moving average of $3.12 and a 200 day simple moving average of $3.66. Health Catalyst has a fifty-two week low of $2.52 and a fifty-two week high of $9.24. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.44.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Engineers Gate Manager LP boosted its holdings in shares of Health Catalyst by 43.0% in the second quarter. Engineers Gate Manager LP now owns 99,240 shares of the company’s stock valued at $374,000 after acquiring an additional 29,865 shares in the last quarter. First Light Asset Management LLC boosted its stake in Health Catalyst by 17.2% during the 2nd quarter. First Light Asset Management LLC now owns 12,230,181 shares of the company’s stock valued at $46,108,000 after purchasing an additional 1,793,374 shares in the last quarter. Jane Street Group LLC bought a new position in Health Catalyst during the 2nd quarter valued at $173,000. The Manufacturers Life Insurance Company boosted its stake in Health Catalyst by 19.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company’s stock valued at $100,000 after purchasing an additional 4,341 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its stake in Health Catalyst by 68.4% during the second quarter. Qube Research & Technologies Ltd now owns 282,281 shares of the company’s stock valued at $1,064,000 after buying an additional 114,626 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.